HAVE WE SHIFTED OUR PARADIGM OF CLOPIDOGREL AS A MANDATORY DRUG IN TREATMENT OF CARDIOLOGICAL PATIENTS AFTER THE INTRODUCTION OF MORE POWERFUL ANTIAGREGANTS?
https://doi.org/10.21518/2307-1109-2017-2-32-42
Abstract
Despite the decline in cardiovascular mortality rate in recent decades due to the widespread use of antihypertensive, hypocholesterolemic and antiplatelet drugs, various manifestations of ischemic heart disease (IHD) retain one-third of the mortality pattern in individuals older than 35 years [1–3]. In regions with a developed health system, cardiovascular mortality is gradually declining. However, death from various manifestations of IHD remains the leading cause of death among adults regardless of income level [4].
About the Author
E. P. PANCHENKO
Myasnikov Cardiology Institute of the National Medical Research Centre for Cardiology of the Ministry of Health of Russia
Russian Federation
MD, Prof.
Russian Federation
MD, Prof.
References
1. Rosamond W et al. Heart Disease and Stroke Statistics—2008 Update: A Report From the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation, 2008, 117: e25–e146.
2. Nichols M, Townsend N, Scarborough P & Rayner M. Cardiovascular disease in Europe 2014: epidemiological update. Eur. Heart J, 2014, 35: 2950–9.
3. Benjamin EJ et al. Heart Disease and Stroke Statistics-2017 Update: A Report From the American Heart Association. Circulation, 2017, 135: e146–e603.
4. Lopez AD, Mathers CD, Ezzati M, Jamison DT & Murray CJL. Global and regional burden of disease and risk factors, 2001: systematic analysis of population health data. Lancet (London, England), 2006, 367: 1747–57.
5. Панченко Е.П. Результаты трёхлетнего наблюдения за амбулаторными больными с клиническими проявлениями атеротромбоза (анализ российской популяции регистра REACH). Кардиология, 2009, 10: 9-14.
6. Steg PG, Bhatt DL, Wilson PWF et al. One-Year Cardiovascular Event Rates in Outpatients With Atherothrombosis. JAMA, 2007, 297: 1197–1206.
7. CAPRIE Steering Committee. A randomised, blinded trial of clopidogrel versus aspirin in patients at risk of ischemic events (CAPRIE). Lancet, 1996, 348: 1329-39.
8. Yusuf S et al. Effects of Clopidogrel in Addition to Aspirin in Patients with Acute Coronary Syndromes without ST-Segment Elevation. N. Engl. J. Med., 2001, 345: 494–502.
9. Sh.Mehta,S.Yusuf, R.Peters et al. Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study. Lancet, 2001, 358: 527-33.
10. Sabatine M et al. Addition of Clopidogrel to Aspirin and Fibrinolytic Therapy for Myocardial Infarction with Elevation. N Engl J Med, 2005, March 9 352.
11. COMMIT (ClOpidogrel and Metoprolol in Myocardial Infarction Trial) collaborative group. Addition of clopidogrel to aspirin in 45852 patients with acute myocardial infarction: randomized placebo-controlled trial. Lancet, 2005: 1607-21.
12. Wallentin L, Becker RC, Budaj A et al. Ticagrelor versus clopidogrel in patients with acure coronary syndromes. N Engl J Med, 2009, 361(11): 1045-1057.
13. Wiviot SD, Braunwald E, McCabe et al. Prasugrel versus clopidogrel in patients with acute coronary syndromes. N Engl J Med, 2007, 357: 2001-15.
14. Mega J, Braunwald E, Wiviott SD et al. Rivaroxaban in patients with a recent acute coronary syndrome. N Engl J Med, 2012, 366: 9-11.
15. Mauri L, Kereiakes D, Yeh R et al. Twelve or 12 months of dual antiplatelet therapyafter drug-eluting stents. N Engl J Med, 2014, 371: 2155-2166.
16. Bonaca M, Bhatt D, Cohen M et al. Long-term use of ticagrelor in patients with prior myocardial infarction. N Engl J Med, 2015, 372: 1791–800.
17. Bhatt DL et al. Clopidogrel and Aspirin versus Aspirin Alone for the Prevention of Atherothrombotic Events. N. Engl. J. Med., 2006, 354: 1706–1717.
18. Stone GW, Maehara A, Lansky AJ et al. A prospective natural-history study of coronary atherosclerosis. N Engl J Med, 2011, 364: 226-235.
19. Udell JA, Bonaca M, Collet J-Ph et al. Long-term dual antiplatelet therapy for secondary prevention of cardiovascular events in the subgroup of patients with previous myocardial infarction: acollaborative meta-analysis of randomized trials. Eur Heart Journal, doi:10.1093/eurheartj/ehv443.
20. 2017 ESC Guidelines for the management of acute myocardial infarction in patients presenting with STsegment elevation. doi:10.1093/eurheartj/ehx393.
21. 2017 ESC fosed update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS. doi:10.1093/eurheartj/ehx419.
22. Bergmeijer Th, Janssen P, Oevelen M et al. Inciedence and Causes for Early Ticagrelor Discontinuation: A “Real-World” Dutch Registry Experience. Cardiology, 2017, 138: 164-167.
23. Biscaglia S, Campo G, Pavasini R et al. Occurrence, causes and outcome after switching from ticagrelor to clopidogrel in real-life scenario: data from a prospective registry. Platelets, 2016. Doi:10.3109/09537104.2015.1119815.
24. Zettler M, Peterson E, McCoy L et al. Switching of adenosine diphosphate receptor inhibitor after hospital discharge among mocardial infarction patients: Longitudinal Assessment of Treatment Patterns and Events after Acute Coronary Syndrome (TRANSLATEACS) obsevational study. Am Heart J, 2017, 183: 62-8.
25. Cuisset T, Deharo P, Quilici J et al. Benefit of switching dual antiplatelet therapy after acute coronary syndrome: the TOPIC (timing of platelet inhibition after acute coronary syndrome) randomized study. Eur Heart Journal, 2017. doi:10.1093/eurheartj/ehx175.
26. International Expert Consensus on Switching Platelet P2Y12 Receptor — Inhibiting Therapies. Circulation, 2017, 136: 00–00. DOI: 10.1161/CIRCULATIONAHA.117.031164.
Review
For citations:
PANCHENKO E.P. HAVE WE SHIFTED OUR PARADIGM OF CLOPIDOGREL AS A MANDATORY DRUG IN TREATMENT OF CARDIOLOGICAL PATIENTS AFTER THE INTRODUCTION OF MORE POWERFUL ANTIAGREGANTS? Aterotromboz = Atherothrombosis. 2017;(2):32-42. (In Russ.) https://doi.org/10.21518/2307-1109-2017-2-32-42
Views:
803
This work is licensed under a Creative Commons Attribution Attribution-NonCommercial-NoDerivs License.
Email this article 